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Abstract— We designed and synthesized a new hetero-bivalent ligand having antagonist properties on both A1 
adenosine and µ opiate receptors with a Ki of 0.8±0.05 and 0.7±0.03 µM, respectively. This bipolar compound 
increases cAMP production both in cells over expressing the µ receptor and in those over expressing the A1 
adenosine receptor and reverses the antalgic effects of µ and A1 adenosine receptors agonist in animals.   
——— 
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The cross talk between different G protein-
coupled receptors (GPCRs) is the source of 
increasing research in the area of simultaneously 
targeting more than one GPCR.1 Most of cross 
talk between different GPCRs concerns cAMP 
production via the modulation of adenylyl-
cyclase activity. There is a great number of 
GPCRs that either stimulates or inhibits adenylyl-
cyclase activity, depending on the nature of the G 
protein (Gs, Gi or other). Among GPCRs, there is evidence that A1ARs and MORs are implicated in such a cross talk and their activation decrease 
cAMP level in the target cells.  
In peripheral nervous system, there is a cross-
tolerance and cross withdrawal between A1ARs and MORs, indicating that these receptors are 
localized on the same primary afferent 
nociceptors and that A1ARs and MORs cooperate as a multiple receptor complex form.2 Our group 
has also demonstrated that the activation of 
MORs increased adenosine concentration in extra 
cellular spaces of the central nervous system, 
suggesting that most effects of opioids are due to 
adenosine release.3 
Based on the A1ARs/MORs cross talk, the aim of this study was to design and to synthesize a 
potential hetero-bivalent A1ARs/MORs ligand and to evaluate its biological effects. Hetero-
bivalent ligand is a single chemical entity that is 
composed of two covalently linked 
pharmacophores with a dual mode of action, 
acting on two different receptor subtypes.1a,1f,4  
Modulating both A1ARs and MORs could have therapeutic application in some diseases. As 
an example, the release of adenosine aggravated 
the hypotension during severe sepsis or septic 
shock, leading to subsequent tissue 
hypoperfusion and ischemia. Most of these 
effects are secondary to the activation of A1 adenosine receptors, explaining the absence of 
response to pressive amines in these patients.5 
Furthermore, naloxone, a µ receptor antagonist 
has been successfully used against the drop of 
blood pressure during septic shock6 or 
 hypovolemic shock,7 suggesting that the release 
of endogenous opioids participates into the 
severity of these syndromes. Thus blocking both 
A1 ARs and MORs may be of a great interest in these pathologies. Modulating both these 
receptors may also be of interest in the area of 
drug-withdrawal therapy.8  
We planed to associate Fentanyl [N-phenyl-N-
(1-phenethyl-4-piperidinyl)propanamide] to the 
adenosine molecule itself (Figure 1). Indeed, 
Fentanyl is one of the most powerful opioid 
analgesics, with a potency approximately eighty 
times that of morphine and forty times that of 
oxycodone.9 Herein, we report the synthesis of a 
bivalent compound (10), its µ opioid (MORs) and 
A1 adenosine (A1AR) receptors binding affinities and its biological properties. 
Having in mind that the main approach to 
discovering AR agonists has been the 
modification of adenosine itself and that N6-cyclopentyladenosine (CPA) derivative displays 
high A1AR selectivity,10 we first turned our attention to the synthesis of compound 10 
presenting a cyclopentyl substitution at the 
adenosine N6-position and an amide bond linker 
at the 5’-position. 
Figure 1. Concept of hetero-bivalent A1ARs/MORs ligand 
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Our retrosynthetic approach for this potential 
hetero-bivalent ligand could involve an 
amidification step between the adenosine 
carboxylic acid 4 and the methyl amino fentanyl 
derivative 8 (Schemes 1 and 2). 
Synthesis of acid 4 (Scheme 1) was now 
needed and started with the conversion of inosine 
1 into the corresponding chloro acetal derivative 
2. Preparation of chloroinosine began with the 
acetylation of inosine with acetic anhydride in the 
presence of triethylamine and DMAP to afford 
triacetylinosine in quantitative yield. The 
conversion into the chloride with thionyl chloride 
was directly followed by a deacetylation using a 
solution of ammonia in methanol to give the 
expected chloroinosine (90% yield over 3 steps). 
Selective protection of the two secondary alcohol 
functions was achieved with dimethoxypropane 
in presence of p-TSA to give 2 in 70 %.11 After 
being subjected to cyclopentylamine in the 
presence of calcium carbonate, compound 2 led 
to the corresponding secondary amine 3 in 98% 
yield. Thereafter the primary alcohol underwent 
an oxidation to the acid 4 under TEMPO-
iodobenzene diacetate conditions12 in 65% yield. 
Attention was next turned to the fentanyl part of 
target molecule 8 (Scheme 2). Reductive 
amination of 4-aminoacetophenone with 
commercially available 1-phenethylpiperidine-4-
one (5) afforded amine 6. 
This secondary amine was next subjected to 
propionylation and led to the formation of the 
desired compound 7 in 95% yield. 
 
 
Scheme 1. Synthesis of adenosyl carboxylic acid 4 
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Reagents and conditions : (a) (1) Ac2O, DMAP, Et3N, ACN, rt, quant.; (2) SOCl2, DMF, DCM, 0 °C then reflux, 90%; (3) NH3/MeOH, 0 °C then 20 °C, quant. (b) dimethoxypropane, p-TSA, acetone, rt, 70%; (c) 
cyclopentylamine, DIEA, EtOH, 80°C, 98%; (d) BAIB, 
TEMPO, ACN/H2O, rt, 65%. 
The latter in the presence of ammonium 
acetate and sodium cyanoborohydride furnished 
subunit 8 in 55% yield. 11 
Scheme 2. Synthesis of methylaminofentanyl 8 
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Reagents and conditions: (a) 5, NaBH(OAc)3, AcOH, DCE, rt, 77%; (b) propionyl chloride, Et3N, DCM, reflux, 95%; (c) NH4OAc, NaBH3CN, MeOH, 50 °C, 55%. 
The synthesis of target 10 (Scheme 3) was 
completed in two steps by using a BOP-assisted 
coupling between acid 4 and amine 813 then a 
deprotection of the acetal moiety using aqueous 
trifluoroacetic acid affording the target molecule 
10 with good overall yield. By using this 
approach this potential hetero-bivalent ligand was 
efficiently synthesized on milligram scale (93% 
HPLC purity grade) in 8 steps.  
 
 
Scheme 3. Synthesis of adenosyl fentanyl 10 
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Reagents and conditions: (a) 7, BOP, Et3N, THF, rt, 77%; (b) 80% TFA, rt, 32%. 
This new hetero-bivalent ligand 10 was then 
submitted to biological evaluation.14 Adenosyl 
fentanyl 10 was first tested using nociceptive 
tests in animals. Adenosyl fentanyl 10 alone had 
no effect on latencies.  
 
 
Figure 2. Results of nociceptive tests in animals 
However it is worth to note that DAMGO, a well 
known synthetic opioid peptide with µ agonist 
properties, co-injected with 10 showed shorter 
latencies than DAMGO alone both in hot plate 
and tail flick tests. Adenosyl fentanyl 10 also 
reversed significantly the increase of latencies 
induced by N6 cyclopentyl adenosine (CPA), an A1 AR agonist (Figure 2). Comparable results 
were obtained using intraperitoneal 
administration of drugs (data not shown). We 
also evaluated the acute toxicity of 10 in animals:  
LD 50 value was >50 µg/mouse (when icv 
administered) and > 500 mg/kg (when ip 
administered). We tested the properties of 10 to 
modulate cAMP production in cell culture. 10 
Activated cAMP production in a dose dependent 
manner both in CHO K1 cells that over expressed 
MORs and in CHO Chem 3 cells that over 
expressed A1ARs, with a maximal stimulation of 
29±7% and 17±3%, respectively.  
  
 
Figure 3. Comparative effects of 10, naloxone and DPCPX 
on cAMP production 
Comparatively, naloxone, a MORs antagonist, 
increased cAMP production with a maximal 
stimulation of 50±16% while 8-cyclopentyl-1,3-
dipropyl-xanthine (DPCPX), an A1 AR antagonist, increased cAMP production with a 
maximal stimulation of 45±8% (Figure 3). 
We also evaluated the affinities (Ki) of drugs 
tested, using binding assay on cell membranes 
(Table). 10 had substantial lower affinities for the 
A1ARs as compared with A1ARs antagonist DPCPX and/or lower affinities for the MORs as 
compared with the MORs antagonist naloxone or 
with the MORs agonist DAMGO. However, its 
affinity was sufficient to produce biological 
effects at reasonable concentrations.  
Table 1: Ki values for drugs at the A1 AR and the MORs 
 Ki A1 AR Ki A2A Ki MORs 
(nM) AR (nM) (nM) 
DPCPX 12.9±3   
Naloxone   1.5±0.2 
DAMGO   3.8±0.7 
10 800±57 >40.000 728±37 
DPCPX: 8-Cyclopentyl-1,3-dipropylxanthine (A1 AR 
antagonist)Naloxone: MORs antagonist; DAMGO: ([D-
Ala2, N-Me Phe4, Gly-ol]enkephalin)( MORs agonist) 
We have synthesized a hetero-bivalent ligand 
10 that have antagonist properties on both A1AR and MORs. Its affinity remained low for the two 
receptors but sufficient to have biological effects 
at reasonable concentration. 10 Reversed 
significantly the antalgic effects of DAMGO or 
CPA and activated cAMP production in both cell 
lines tested. To the best of our knowledge, 
adenosyl fentanyl 10 constitutes the first drug 
that blocks both MORs and A1ARs. Multivalent-ligands are also called hybrid molecules, and are 
defined as chemical entities having different 
biological effects.4c There is evidence that 
adenosine via A1ARs, is implicated in the modulation of opiates action in the central 
nervous system.24 Morphine25 and adenosine26 
inhibit Ca2+ dependent NT release; this inhibition 
is blocked by theophiline an adenosine receptors 
antagonist.20 A1ARs and MORs are both implicated in septic or hypovolemic shock, 5,6,7 
withdrawal, 8,21 mood regulation22 and pain.24,30 
Thus to have drugs which modulate both A1AR and MORs at one’s disposal, could be interesting 
in these area. After these encouraging 
preliminary results we have embarked in more 
systematic SAR study in design more active and 
selective hybrid targets. Theses results will be 
reported in due course. 
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